Rotigotine for restless legs syndrome.
Restless legs syndrome (RLS) is a neurological disorder related to abnormal and unpleasant sensations and movements in the legs. It usually occurs at nighttime and thus has a detrimental impact on the ability to sleep, leading to poor patient quality of life. UCB has been developing rotigotine transdermal patch system (Neupro; SPM-962) as a treatment for RLS. This system is designed to replace levels of dopamine in the body via once-daily application of the patch, in a bid to restore proper motor functioning. The rotigotine patch has been authorized for the treatment of RLS since August 2008.
Davies
Shelley
S
Medical Information Department, Thomson Reuters, Barcelona, Spain. scientific.prousjournals@thomsonreuters.com
D000279:Administration, Cutaneous; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004304:Dosage Forms; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012148:Restless Legs Syndrome / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D018491:Dopamine Agonists; D004304:Dosage Forms; D013764:Tetrahydronaphthalenes; D013876:Thiophenes; C047508:rotigotine